This website will offer limited functionality in this browser. We only support the recent versions of major browsers like Chrome, Firefox, Safari, and Edge.
Dr.Gregory K. Bell is quoted in this article published by BioPharm International about the regulatory and legal issues associated with bringing recent biosimilars and biobetters to market. Click below to read the article.
Group Vice President and Life Sciences Practice Leader
Boston
+1-617-425-3357 gbell@crai.comFocusing on the intersection of academic research and litigation matters, Daniel Shack and Annabelle Fowler highlight key research developments and discussion...
US policy has long recognized this challenge, beginning with the Orphan Drug Act of 1983 and continuing with recent exemptions for certain orphan indications...
Join CRA and leading European payer experts for a 30-minute virtual webinar as we explore how growing competitive dynamics are reshaping the rare diseases...
CRA is a proud sponsor of the conference focusing on the intersection of intellectual property and the biopharmaceutical industry, and will explore the law,...
